Developing a targeted gene editing tool for mosquitoes that spread diseases.
Official title: A Cell-specific modified CRISPR/Cas9 system for conditional gene disruption in Aedes aegypti
Funded at Brandeis University · NIH-10739805 · Data updated 2026-11-12
This study is working on a special tool to change the genes of yellow fever mosquitoes, which spread diseases like dengue and chikungunya, to help scientists learn more about them and find better ways to control their populations and reduce the spread of these illnesses.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brandeis University NIH-funded |
| Lab location | 1 site (Waltham, United States) |
| Project start | November 14, 2022 |
| Project end | October 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $203,125 |
| NIH project number | 5R21AI174516-02 |
| Project ID | NIH-10739805 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include individuals living in regions affected by mosquito-borne diseases such as dengue and chikungunya.
✕Less likely to help
Patients who do not live in areas where Aedes aegypti is prevalent may not receive direct benefits from this research.
What this research studies
This research focuses on creating a modified CRISPR/Cas9 system specifically designed for the yellow fever mosquito, Aedes aegypti, which is known to transmit diseases like dengue and chikungunya. By enhancing the precision of gene disruption in these mosquitoes, the project aims to better understand their biology and behavior, which could lead to more effective control strategies against mosquito-borne diseases. The approach involves developing a toolkit that allows researchers to target specific cells within the mosquito, making it easier to study the effects of gene disruption. This could ultimately inform new methods for controlling mosquito populations and reducing disease transmission.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for controlling mosquito populations and reducing the incidence of diseases they transmit.
How similar studies have gone: Other research has shown success with CRISPR/Cas9 technology in various organisms, indicating potential for this novel approach in mosquitoes.
Where this research is happening
-
Brandeis University
Waltham, United States Active
Researchers
- Principal investigator: Garrity, Paul — Brandeis University
- Study coordinator: Garrity, Paul
Related research
Other NIH-funded projects on the same topics.
-
Unwinding SNAP aid and its effect on healthcare and disparities
A large study will look at how cutting back food assistance like SNAP changes healthcare use and outcomes, especially for people with differing levels of food insecurity.
-
Roles of Recycling Endosomes in Neuronal EV Cargo Traffic
A scientist at Brandeis University is studying how brain cells control the tiny vesicles they release, which may affect memory loss in Alzheimer’s disease.
-
Sulfur-stabilized HIV glycoconjugates to help create powerful bnAbs
Researchers are testing sugar-coated HIV vaccine components in animals to see if they can better trigger broadly-protective antibodies.
-
Cycling Molecular Assemblies to Target Golgi Traffic in Cancer Cells
A novel, first-of-its-kind approach uses tiny, self-organizing molecular structures to selectively disrupt Golgi trafficking in cancer cells, aiming to influence how cancer cells grow and respond to signals.
-
How low oxygen and genetic tweaks may repair mitochondrial problems linked to Alzheimer’s and other disorders
A Johns Hopkins-style? (Note: institution specified later) patient-facing overview: researchers will study tiny cell power stations in mitochondria to see if low-oxygen conditions and specific genetic changes can fix problems associated with Alzheimer's disease and related dementias.
-
Synthesis of thioaminoketal antimicrobial peptides and how they work
Researchers are developing new antimicrobial peptides called sactipeptides and figuring out precisely how they kill bacteria.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.